Active, not recruitingPHASE1, PHASE2NCT04913337
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NGM Biopharmaceuticals, Inc
- Principal Investigator
- Chief Medical OfficerNGM Biopharmaceuticals, Inc
- Intervention
- NGM707(drug)
- Enrollment
- 179 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (23)
- NGM Clinical Study Site, Los Angeles, California, United States
- NGM Clinical Study Site, Newport Beach, California, United States
- NGM Clinical Study Site, Santa Monica, California, United States
- NGM Clinical Study Site, Santa Rosa, California, United States
- NGM Clinical Study Site, Lone Tree, Colorado, United States
- NGM Clinical Study Site, Washington D.C., District of Columbia, United States
- NGM Clinical Study Site, Sarasota, Florida, United States
- NGM Clinical Study Site, Baltimore, Maryland, United States
- NGM Clinical Study Site, Boston, Massachusetts, United States
- NGM Clinical Study Site, Grand Rapids, Michigan, United States
- NGM Clinical Study Site, Omaha, Nebraska, United States
- NGM Clinical Study Site, Albany, New York, United States
- NGM Clinical Study Site, Greenville, South Carolina, United States
- NGM Clinical Study Site, Dallas, Texas, United States
- NGM Clinical Study Site, Houston, Texas, United States
- +8 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04913337 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited